BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial

Reuters

Feb 03

BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial

Feb 3 (Reuters) - Pfizer Inc PFE.N:

PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIAL
PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIAL
PFIZER - STUDY SHOWS 12.3% WEIGHT LOSS AT WEEK 28
PFIZER - 10 PHASE 3 TRIALS WITH PF’3944 EXPECTED IN 2026
PFIZER - STUDY MET PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT WEIGHT REDUCTION AT 28 WEEKS WITH A COMPETITIVE TOLERABILITY PROFILE
PFIZER - PF’3944 MAINTAINS FAVORABLE SAFETY PROFILE THROUGH WEEK 28
PFIZER - PLANNING AN EXPANSIVE OBESITY DEVELOPMENT PROGRAM ACROSS ITS PIPELINE, WITH PLANS TO ADVANCE 20+ TRIALS IN 2026
PFIZER: ACROSS ARMS 1 AND 3, FIVE TOTAL PARTICIPANTS DISCONTINUED FROM TREATMENT DUE TO ADVERSE EVENTS IN WEEKLY PHASE
PFIZER: ACROSS ARMS 1 AND 3 FIVE TOTAL PARTICIPANTS DISCONTINUED FROM TREATMENT DUE TO AES IN MONTHLY PHASE

Source text: ID:nBw15qHG9a

Further company coverage: PFE.N

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608587167"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608587167\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608587167?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608587167","market":"fut","top_or_hot":-1,"title":"BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial</title></head><body><p><span>Feb 3 (Reuters)</span><span> - </span>Pfizer Inc <span>PFE.N</span>:</p><ul><li><p>PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIAL</p></li><li><p>PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIAL</p></li><li><p>PFIZER - STUDY SHOWS 12.3% WEIGHT LOSS AT WEEK 28</p></li><li><p>PFIZER - 10 PHASE 3 TRIALS WITH PF’3944 EXPECTED IN 2026</p></li><li><p>PFIZER - STUDY MET PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT WEIGHT REDUCTION AT 28 WEEKS WITH A COMPETITIVE TOLERABILITY PROFILE</p></li><li><p>PFIZER - PF’3944 MAINTAINS FAVORABLE SAFETY PROFILE THROUGH WEEK 28</p></li><li><p>PFIZER - PLANNING AN EXPANSIVE OBESITY DEVELOPMENT PROGRAM ACROSS ITS PIPELINE, WITH PLANS TO ADVANCE 20+ TRIALS IN 2026</p></li><li><p>PFIZER:  ACROSS ARMS 1 AND 3, FIVE TOTAL PARTICIPANTS DISCONTINUED FROM TREATMENT DUE TO ADVERSE EVENTS IN WEEKLY PHASE</p></li><li><p>PFIZER: ACROSS ARMS 1 AND 3 FIVE TOTAL PARTICIPANTS DISCONTINUED FROM TREATMENT DUE TO AES IN MONTHLY PHASE</p></li></ul><p>Source text: <span>ID:nBw15qHG9a</span></p><p>Further company coverage: <span>PFE.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-03 21:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial</title></head><body><p><span>Feb 3 (Reuters)</span><span> - </span>Pfizer Inc <span>PFE.N</span>:</p><ul><li><p>PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIAL</p></li><li><p>PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIAL</p></li><li><p>PFIZER - STUDY SHOWS 12.3% WEIGHT LOSS AT WEEK 28</p></li><li><p>PFIZER - 10 PHASE 3 TRIALS WITH PF’3944 EXPECTED IN 2026</p></li><li><p>PFIZER - STUDY MET PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT WEIGHT REDUCTION AT 28 WEEKS WITH A COMPETITIVE TOLERABILITY PROFILE</p></li><li><p>PFIZER - PF’3944 MAINTAINS FAVORABLE SAFETY PROFILE THROUGH WEEK 28</p></li><li><p>PFIZER - PLANNING AN EXPANSIVE OBESITY DEVELOPMENT PROGRAM ACROSS ITS PIPELINE, WITH PLANS TO ADVANCE 20+ TRIALS IN 2026</p></li><li><p>PFIZER:  ACROSS ARMS 1 AND 3, FIVE TOTAL PARTICIPANTS DISCONTINUED FROM TREATMENT DUE TO ADVERSE EVENTS IN WEEKLY PHASE</p></li><li><p>PFIZER: ACROSS ARMS 1 AND 3 FIVE TOTAL PARTICIPANTS DISCONTINUED FROM TREATMENT DUE TO AES IN MONTHLY PHASE</p></li></ul><p>Source text: <span>ID:nBw15qHG9a</span></p><p>Further company coverage: <span>PFE.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1057294990.SGD","symbol_name":"Blackrock World Healthscience A2 SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUA7ZLCMT:1","article_id":"2608587167","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608587167","pubTimestamp":1770124867,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B TrialFeb 3 (Reuters) - Pfizer Inc PFE.N:PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4550":"红杉资本持仓","BK4588":"碎股","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4568":"美国抗疫概念","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999002232.USD":"Allianz Global High Payout USD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4007":"制药","SG9999002224.SGD":"Allianz Global High Payout SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4581":"高盛持仓","BK4599":"减肥药","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","PFE":"辉瑞","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","BK4585":"ETF&股票定投概念","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","BK4534":"瑞士信贷持仓","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0058720904.USD":"联博国际健康护理基金A","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","BK4592":"伊斯兰概念"},"translate_title":"简报-辉瑞超长效可注射Glp-1 RA在2B期试验中显示减肥结果","themeId":"3bb44f7c125c909d9d8be6d6af593a67","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1.98},"content_text":"BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B TrialFeb 3 (Reuters) - Pfizer Inc PFE.N:PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIALPFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIALPFIZER - STUDY SHOWS 12.3% WEIGHT LOSS AT WEEK 28PFIZER - 10 PHASE 3 TRIALS WITH PF’3944 EXPECTED IN 2026PFIZER - STUDY MET PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT WEIGHT REDUCTION AT 28 WEEKS WITH A COMPETITIVE TOLERABILITY PROFILEPFIZER - PF’3944 MAINTAINS FAVORABLE SAFETY PROFILE THROUGH WEEK 28PFIZER - PLANNING AN EXPANSIVE OBESITY DEVELOPMENT PROGRAM ACROSS ITS PIPELINE, WITH PLANS TO ADVANCE 20+ TRIALS IN 2026PFIZER:  ACROSS ARMS 1 AND 3, FIVE TOTAL PARTICIPANTS DISCONTINUED FROM TREATMENT DUE TO ADVERSE EVENTS IN WEEKLY PHASEPFIZER: ACROSS ARMS 1 AND 3 FIVE TOTAL PARTICIPANTS DISCONTINUED FROM TREATMENT DUE TO AES IN MONTHLY PHASESource text: ID:nBw15qHG9aFurther company coverage: PFE.N ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}